Company attributes
Venture Capital Firm attributes
Other attributes
Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1 billion under management. Vivo Capital makes investments from its $375M seventh fund into private and public healthcare companies in the U.S. and greater China. Vivo Capital has offices in Palo Alto, California, Shanghai, Chengdu, and Beijing, China.
Vivo's portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices. Vivo Capital has made 105 investments and has raised a total of $5.4B across 8 funds.
Vivo making investments from its $1.4B Vivo Capital Fund IX into private healthcare companies, from its $635M Vivo Opportunity Fund into public healthcare companies, and from its $100M Vivo Innovation (PANDA) Fund into early-stage healthcare companies.
Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Their growth capital investments help portfolio companies accelerate revenue ramp or fund product development to drive value creation. Their private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. They invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.
Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.
Vivo Innovation Fund (i.e., Vivo PANDA Fund) focuses on investing in venture stage companies with the potential to develop healthcare technologies or products. The fund typically invests in early stage (i.e. Series A) financing rounds.
